ANI Pharmaceuticals, Inc.ANIPNASDAQ
LOADING
|||
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +12.52% | +44.75% | +43.43% | +53.12% | +53.58% |
| Gross Profit Growth | +1.83% | +40.98% | +40.57% | +70.22% | +31.12% |
| EBITDA Growth | -140.52% | -32.14% | +8.38% | +129.95% | +0.00% |
| Operating Income Growth | -214.32% | -165.09% | +28.96% | +168.76% | +0.00% |
| Net Income Growth | -343.12% | -989.70% | -13.87% | +0.00% | +0.00% |
| EPS Growth | -354.00% | -1495.94% | -16.67% | +0.00% | +0.00% |
| EPS Diluted Growth | -354.00% | -1510.26% | -16.87% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +2.76% | +2.33% | +2.66% | +2.66% | +3.45% |
| Weighted Average Shares Diluted Growth | +1.46% | +1.18% | +3.21% | +5.11% | +8.70% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -61.22% | -64.55% | +91.53% | +335.35% | +253.17% |
| Free Cash Flow Growth | -72.26% | -66.52% | +10.64% | +431.45% | +394.54% |
| Receivables Growth | +9.80% | +36.80% | +27.79% | +35.86% | +28.65% |
| Inventory Growth | +38.89% | +23.01% | +20.71% | +10.26% | -1.06% |
| Asset Growth | +44.66% | +41.94% | +41.32% | +45.86% | +9.38% |
| Book Value per Share Growth | -7.80% | -8.48% | -9.40% | -6.44% | +13.50% |
| Debt Growth | +118.75% | +118.47% | +118.18% | +117.91% | -48.41% |
| R&D Expense Growth | -8.93% | +68.70% | +0.50% | +126.63% | +21.48% |
| SG&A Expenses Growth | +88.24% | +56.81% | +59.36% | +54.81% | -3.06% |